BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

Covid vaccine stocks surged Friday after a new study suggested an added benefit of the updated omicron-targeting boosters. The post This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters appeared first on Investor's Business Daily.

This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters

Pfizer

First the good news: Pfizer Inc. and Germany-based partner BioNTech SE said updated trial data for their omicron BA.4/BA.5-adapted bivalent booster showed a “substantially higher” immune response in adults than the original COVID-19 vaccine.

Pfizer-BioNTech bivalent booster shows higher immune response, but new COVID cases climb back above 40,000 a day

Stocks in China are abuzz with reopening rumors this week, leading investors to speculate on their subsequent rallies and whether or not they will be short-lived.

BioNTech Stock Boosted on Vaccine Buzz

Pfizer Inc. PFE, -0.21% and Germany-based partner BioNTech SE BNTX, +2.64% said new data from a Phase 2/3 trial showed that the booster for companies' omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine demonstrated a "robust neutralizing immune response" after one month. The companies said immune responses for those getting the booster were "substantially higher" than for those who only received the original COVID-19 vaccine, with similar safety and tolerability profiles.

Pfizer, BioNTech stocks rally after announcing positive trial data on BA.4/BA.5 bivalent booster shot

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated data from a Phase 2/3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30-µg booster dose of the companies' Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)).

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

German Chancellor Olaf Scholz announced an agreement on Friday to let expatriates in China use the COVID-19 vaccine from Germany's BioNTech and pressed for Beijing to allow the shot to be made freely available to Chinese citizens.

Scholz secures agreement allowing expats in China to use BioNTech COVID-19 vaccine

Shares of Germany-based BioNTech SE BNTX, +2.64% surged 5.1% toward a three-month high in premarket trading Friday, after The Wall Street Journal reported that China agreed to approve the biotechnology company's COVID-19 vaccines for foreign residents in China. Pfizer Inc.'s stock PFE, -0.21% climbed 1.5% ahead of the open, as BioNTech had partnered with the U.S. drug giant to develop COVID-19 vaccines.

BioNTech stock surges toward 3-month high after report China agrees to approve its COVID vaccine for foreigners

BioNTech will initially import its COVID-19 vaccine into China, said a spokesperson for the company on Friday, after German Chancellor Olaf Scholz said during a visit to Beijing that China would allow expatriates to receive the German company's vaccine.

BioNTech spokesperson: Vaccine to initially be imported to China

China agreed to approve BioNTech's Covid-19 vaccines for foreign residents in China, German Chancellor Olaf Scholz said in a news conference in Beijing, after he met Chinese leader Xi Jinping.

China Agrees to Approve BioNTech's Covid-19 Vaccine for Foreigners, German Chancellor Says

Pfizer and BioNTech started testing a combined flu and Covid vaccine on Thursday, helping BNTX stock pare earlier Moderna-inspired losses. The post BioNTech Shares Up On Hope For Combined Flu, Covid Shot appeared first on Investor's Business Daily.

BioNTech Shares Up On Hope For Combined Flu, Covid Shot

U.S. drugmaker Pfizer Inc and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.

Pfizer, BioNTech start COVID-flu combination vaccine study

Swiss drugs regulator Swissmedic said on Wednesday it is examining potential risks in connection with bubbles that appeared in vials of COVID-19 vaccine boosters retooled to target the Omicron variant of the coronavirus.

Swiss drugs regulator looking into bubbles in COVID booster vials

BioNTech has a burgeoning oncology portfolio up its sleeve.

Is BioNTech a Good Long-Term Buy?

Mainz, Germany, October 24, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2022 on Monday, November 7th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the third quarter 2022.

BioNTech to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022

Novavax

Stocks were set to open lower today, but the market seems to have found its groove. Everything from tech stocks to vaccine stocks are moving higher.

Why Are Vaccine Stocks MRNA, PFE, BNTX, NVAX Up Today?

NEW YORK and MAINZ, Germany, October 19, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization (MA) for a 3-µg dose of COMIRNATY® (COVID-19 vaccine, mRNA), which is based on the wild-type spike protein of SARS-CoV-2, as a three-dose series for children ages 6 months to less than 5 years (also referred to as 6 months through 4 years of age). The European Commission will review the CHMP recommendation and is expected to make a final decision soon.

Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union

Anticipating a surge of COVID-19 infections later this year, the FDA broadens the label of authorized Omicron-based BA.4/BA.5 adapted bivalent boosters to include children as young as five years.

FDA Allows Emergency Use of Omicron-Based COVID Jabs in Kids

Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants, generated a strong immune response and was well tolerated in testing on humans.

Pfizer, BioNTech's updated booster protects against Omicron in human trial

Pfizer Inc. PFE, +0.26% and German partner BioNTech SE BNTX, +5.53% said Thursday early data from a Phase 2/3 clinical trial of their omicron BA.4/BA.5-adapated bivalent booster showed positive results in treating individuals aged 18 and older. The data collected 7 days after administering a 30-ug booster dose showed a “substantial increase” in neutralizing antibodies.

Pfizer and BioNTech report positive data in trial of omicron-targeting bivalent booster in individuals aged 18 and older

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating the safety, tolerability, and immunogenicity of the companies' Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)).

Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 5.37% to $136.45 going into the close of Wednesday's trading session after the FDA granted Emergency Use Authorization to the company's 10-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.

Why Pfizer Partner BioNTech SE Shares Are Trading Higher - BioNTech (NASDAQ:BNTX)

The Centers for Disease Control and Prevention officially signed off on allowing children as young as 5 years old to get an updated COVID-19 booster shot. CDC Director Rochelle Walensky signed the decision memo on Wednesday afternoon, the same day that the Food and Drug Administration expanded the authorizations for Moderna Inc. MRNA, +7.75% and BioNTech SE BNTX, +4.97% /Pfizer Inc.'s PFE, +0.66% updated COVID-19 boosters.

CDC officially recommends new boosters for young children

Like Moderna's and Pfizer's updated vaccines for adults, the child doses target newer strains of COVID-19.

FDA Authorizes New COVID Boosters for Kids

Shares of Pfizer Inc. PFE, +1.99% climbed 2.2% and BioNTech SE BNTX, +4.87% hiked up 5.5% in morning trading Wednesday, after the companies said the U.S. Food and Drug Administration has granted Emergency Use Authorization (EUA) for its omicron bivalent COVID-19 booster vaccine for children aged 5 through 11. The drug makers said pending recommendation from the Centers for Disease Control and Prevention (CDC), the 10-ug booster doses, adapted for the BA.4 and BA.5 subvariants, will be shipped immediately.

Pfizer, BioNTech stocks surge after FDA grants emergency use of BA.4, BA.5 adapted booster shots in children

Uptake of the retooled coronavirus vaccine among Americans 12 years and older has lagged.

News for BioNTech SE Stock (BNTX)